Menu
Search
|

Menu

Close
X

Perrigo Company PLC PRGO.N (New York Stock Exchange)

55.96 USD
+0.00 (+0.00%)
As of Sep 13
Previous Close 55.96
Open 56.48
Volume 332,906
3m Avg Volume 345,480
Today’s High 57.50
Today’s Low 54.87
52 Week High 75.71
52 Week Low 36.33
Shares Outstanding (mil) 135.99
Market Capitalization (mil) 7,376.17
Forward P/E 64.84
Dividend (Yield %) 0.21 ( 1.55 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.92 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY19
1,174
FY18
4,732
FY17
4,946
FY16
5,281
EPS (USD)
FY19
0.469
FY18
0.939
FY17
0.950
FY16
-27.988
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
64.84
33.85
Price to Sales (TTM)
vs sector
1.57
7.90
Price to Book (MRQ)
vs sector
1.29
4.38
Price to Cash Flow (TTM)
vs sector
14.06
23.70
Total Debt to Equity (MRQ)
vs sector
56.45
17.64
LT Debt to Equity (MRQ)
vs sector
48.24
12.61
Return on Investment (TTM)
vs sector
1.17
12.69
Return on Equity (TTM)
vs sector
1.91
17.13

EXECUTIVE LEADERSHIP

Murray Kessler
President, Chief Executive Officer, Director, Since 2018
Salary: $277,692.00
Bonus: $349,315.00
Raymond Silcock
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
James Michaud
Chief Human Resource Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
Thomas Farrington
Executive Vice President, Chief Information Officer, Since 2015
Salary: --
Bonus: --
James Dillard
Executive Vice President, Chief Scientific Officer, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

The Sharp Building, Hogan Place
DUBLIN     D02 TY74

Phone: +3531.7094000

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. The CHC segment is focused on the sale of OTC store brand products. The BCH segment develops, manufactures, markets and distributes various European OTC brands. The Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs. The Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri.

SPONSORED STORIES